TLR4 expression and functionality are downregulated in glioblastoma cells and in tumor-associated macrophages: A new mechanism of immune evasion?
Aged
Animals
Brain Neoplasms
/ immunology
Cell Line
Cell Line, Tumor
Cell Proliferation
/ physiology
Down-Regulation
/ immunology
Female
Glioblastoma
/ immunology
Humans
Immune Evasion
/ immunology
Male
Mice
Mice, Inbred C57BL
Middle Aged
Signal Transduction
/ immunology
Toll-Like Receptor 4
/ immunology
Tumor Microenvironment
/ immunology
Tumor-Associated Macrophages
/ immunology
Chemoresistance
Glioblastoma
Immune evasion
Macrophages
TLR4
Journal
Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
received:
12
10
2020
revised:
30
03
2021
accepted:
22
04
2021
pubmed:
2
5
2021
medline:
18
11
2021
entrez:
1
5
2021
Statut:
ppublish
Résumé
Glioblastoma (GB) is the most common and aggressive form of primary brain tumor, in which the presence of an inflammatory environment, composed mainly by tumor-associated macrophages (TAMs), is related to its progression and development of chemoresistance. Toll-Like Receptors (TLRs) are key components of the innate immune system and their expression in both tumor and immune-associated cells may impact the cell communication in the tumor microenvironment (TME), further modeling cancer growth and response to therapy. Here, we investigated the participation of TLR4-mediated signaling as a mechanism of induced-immune escape in GB. Initially, bioinformatics analysis of public datasets revealed that TLR4 expression is lower in GB tumors when compared to astrocytomas (AST), and in a subset of TAMs. Further, we confirmed that TLR4 expression is downregulated in chemoresistant GB, as well as in macrophages co-cultured with GB cells. Additionally, TLR4 function is impaired in those cells even following stimulation with LPS, an agonist of TLR4. Finally, experiments performed in a cohort of clinical primary and metastatic brain tumors indicated that the immunostaining of TLR4 and CD45 are inversely proportional, and confirmed the low TLR4 expression in GBs. Interestingly, the cytoplasmic/nuclear pattern of TLR4 staining in cancer tissues suggests additional roles of this receptor in carcinogenesis. Overall, our data suggest the downregulation of TLR4 expression and activity as a strategy for GB-associated immune escape. Additional studies are necessary to better understand TLR4 signaling in TME in order to improve the benefits of immunotherapy based on TLR signaling.
Identifiants
pubmed: 33932524
pii: S0925-4439(21)00088-0
doi: 10.1016/j.bbadis.2021.166155
pii:
doi:
Substances chimiques
TLR4 protein, human
0
Toll-Like Receptor 4
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
166155Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.